-
公开(公告)号：US10961215B2
公开(公告)日：2021-03-30
申请号：US16341602
申请日：2017-10-09
发明人： Michael T. Rudd , Zhaoyang Meng , Jenny Wai , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Shawn J. Stachel , Yongxin Han , Paul Tempest , Jiuxiang Zhu , Xuewang Xu
IPC分类号： C07D401/04 , C07D211/26 , C07D405/14
摘要： In its many embodiments, the present invention provides certain substituted N-aryl and N-heteroaryl piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R6 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
-
2.发明申请公开(公告)号：US20200247754A1
公开(公告)日：2020-08-06
申请号：US16341595
申请日：2017-10-09
申请人： Michael T. RUDD , Zhaoyang MENG , Jenny WAI , David Jonathan BENNETT , Edward J. BRNARDIC , Nigel J. LIVERTON , Shawn J. STACHEL , Yongxin HAN , Paul TEMPEST , Jiuxiang ZHU , Xuewang XU , Bin ZHU , Merck Sharp & Dohme Corp.
发明人： Michael T. Rudd , Zhaoyang Meng , Jenny Wai , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Shawn J. Stachel , Yongxin Han , Paul Tempest , Jiuxiang Zhu , Xuewang Xu , Bin Zhu
IPC分类号： C07D221/20 , C07D401/12 , C07D417/12 , C07D405/12 , C07D211/22 , C07D401/14 , C07D417/14
摘要： In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
-
3.发明申请公开(公告)号：US20200039951A1
公开(公告)日：2020-02-06
申请号：US16341602
申请日：2017-10-09
发明人： Michael T. Rudd , Zhaoyang Meng , Jenny Wai , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Shawn J. Stachel , Yongxin Han , Paul Tempest , Jiuxiang Zhu , Xuewang Xu
IPC分类号： C07D401/04 , C07D405/14 , C07D211/26
摘要： In its many embodiments, the present invention provides certain substituted N-aryl and N-heteroaryl piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, L1, Q, R5 and R6 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, may be useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
-
4.发明申请TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权四环杂环化合物及其用于治疗病毒性疾病的方法公开(公告)号：US20140213571A1
公开(公告)日：2014-07-31
申请号：US14343450
申请日：2012-08-20
发明人： Nigel J. Liverton , Casey Cameron McComas , Joerg Habermann , Uwe Koch , Frank Narjes , Peng Li , Xuanjia Peng , Richard Soll , Hao Wu , Anandan Palani , Shuwen He , Xing Dai , Hong Liu , Zhong Lai , Clare London , Dong Xiao , Nicolas Zorn , Ravi Nargund
IPC分类号： A61K31/553 , A61K31/519 , A61K31/437 , A61K31/407 , C07D498/22 , C07D498/14 , C07D491/147 , C07D491/052 , A61K45/06 , A61K31/5365 , C07D498/04
CPC分类号： A61K31/553 , A61K31/407 , A61K31/437 , A61K31/519 , A61K31/5365 , A61K45/06 , C07D491/052 , C07D491/147 , C07D498/04 , C07D498/14 , C07D498/22 , Y02A50/387 , Y02A50/389 , Y02A50/395 , A61K2300/00
摘要： The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
摘要翻译： 本发明涉及可用作丙型肝炎病毒（HCV）NS5B聚合酶抑制剂，这种化合物的合成以及这些化合物用于抑制HCV NS5B聚合酶活性用于治疗或预防HCV感染的式（I）化合物 并用于在基于细胞的系统中抑制HCV病毒复制和/或病毒生产。
-
公开(公告)号：US09738661B2
公开(公告)日：2017-08-22
申请号：US14638733
申请日：2015-04-03
发明人： Nigel J. Liverton , Vincenzo Summa , Steven Harper , John A. McCauley , Joseph J. Romano , Michael T. Rudd
IPC分类号： A61K31/519 , C07D498/22 , C07D498/08 , C07D498/18 , C07K5/083 , C07K5/087 , A61K31/407 , A61K31/4192 , A61K31/437 , A61K31/439 , A61K45/06 , A61K38/00
CPC分类号： C07D498/22 , A61K31/407 , A61K31/4192 , A61K31/437 , A61K31/439 , A61K38/00 , A61K45/06 , C07D498/08 , C07D498/18 , C07K5/0804 , C07K5/0806 , C07K5/0808 , C07K5/0812
摘要： The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
-
公开(公告)号：US20150266897A1
公开(公告)日：2015-09-24
申请号：US14638733
申请日：2015-04-03
发明人： Nigel J. Liverton , Vincenzo Summa , Maria Emilia Di Francesco , Marco Ferrara , Kevin F. Gilbert , Steven Harper , John A. McCauley , Charles J. McIntyre , Alessia Petrocchi , Marco Pompei , Joseph J. Romano , Michael T. Rudd , John W. Butcher , M. Katharine Holloway
IPC分类号： C07D498/22 , A61K31/437 , A61K31/439 , C07D498/08 , A61K31/407 , A61K31/4192 , C07D498/18 , A61K45/06
CPC分类号： C07D498/22 , A61K31/407 , A61K31/4192 , A61K31/437 , A61K31/439 , A61K38/00 , A61K45/06 , C07D498/08 , C07D498/18 , C07K5/0804 , C07K5/0806 , C07K5/0808 , C07K5/0812
摘要： The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
摘要翻译： 本发明涉及可用作丙型肝炎病毒（HCV）NS3蛋白酶抑制剂及其合成及其用于治疗或预防HCV感染的用途的式（I）的大环化合物。
-
7.发明授权公开(公告)号：US11655216B2
公开(公告)日：2023-05-23
申请号：US16341595
申请日：2017-10-09
申请人： Merck Sharp & Dohme Corp. , Michael T. Rudd , Zhaoyang Meng , Jenny Wai , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Shawn J. Stachel , Yongxin Han , Paul Tempest , Jiuxiang Zhu , Xuewang Xu , Bin Zhu
发明人： Michael T. Rudd , Zhaoyang Meng , Jenny Wai , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Shawn J. Stachel , Yongxin Han , Paul Tempest , Jiuxiang Zhu , Xuewang Xu , Bin Zhu
IPC分类号： C07D221/20 , C07D401/12 , C07D417/12 , C07D405/12 , C07D211/22 , C07D401/14 , C07D417/14
CPC分类号： C07D221/20 , C07D211/22 , C07D401/12 , C07D401/14 , C07D405/12 , C07D417/12 , C07D417/14
摘要： In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
-
公开(公告)号：US10894775B2
公开(公告)日：2021-01-19
申请号：US16341591
申请日：2017-10-09
申请人： Merck Sharp & Dohme Corp. , Michael T. Rudd , Zhaoyang Meng , Jenny Wai , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Shawn J. Stachel , Yongxin Han , Paul Tempest , Jiuxiang Zhu , Xuewang Xu , Bin Zhu , Chuanman Huang
发明人： Michael T. Rudd , Zhaoyang Meng , Jenny Wai , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Shawn J. Stachel , Yongxin Han , Paul Tempest , Jiuxiang Zhu , Xuewang Xu , Bin Zhu , Chuanman Huang
IPC分类号： C07D221/20 , C07D211/16 , C07D211/96
摘要： In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
-
9.发明申请公开(公告)号：US20180305332A1
公开(公告)日：2018-10-25
申请号：US15774655
申请日：2016-11-07
发明人： Shawn J. Stachel , David Jonathan Bennett , Edward J. Brnardic , Nigel J. Liverton , Peter J. Manley , Zhaoyang Meng , Kausik K. Nanda , Michael T. Rudd , Jenny Wai
IPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D471/10 , C07D417/14 , C07D405/14
CPC分类号： C07D401/04 , A61K31/451 , C07D211/06 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/10
摘要： In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, L, R4, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.021 秒)
